GlassScriptPhysician profile
Ashiya Khan
NPI 1346892049
$1,322.90
in general payments reported to CMS, 2019-2025
18 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.11 · 2023: $547 · 2024: $474 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $361.50 | 2023-2024 | Lifevest |
| Philips North America LLC | $143.91 | 2024 | (Bh4) Igt Devices Undivided |
| Sanofi-Aventis U.S. LLC | $132.71 | 2024 | |
| Janssen Scientific Affairs, LLC | $124.88 | 2023 | Xarelto |
| Abiomed | $119.36 | 2023 | Impella |
| Medtronic, INC. | $83.34 | 2024 | Cobalt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $48.85 | 2025 | Lokelma, Farxiga |
| Pfizer INC. | $46.90 | 2022-2025 | |
| Lantheus Medical Imaging, INC. | $43.27 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $33.65 | 2025 | Amvuttra |
| Amgen INC. | $32.89 | 2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $30.90 | 2025 | Opsynvi, Uptravi |
| Scpharmaceuticals INC. | $24.16 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.60 | 2025 | |
| Novo Nordisk INC | $21.16 | 2025 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $20.33 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $19.40 | 2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $14.09 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashiya Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.